Hepatic arterial infusion chemotherapy for advanced XXXX with @entity715 : analysis of 48 cases.

@entity1 @entity900 @entity74 @entity157 @entity99 @entity715 @entity1487
BACKGROUND: The prognosis of @entity1 with @entity157 ( @entity157 ) with @entity715 ( @entity715 ) is extremely poor. The aim of this study was to elucidate the efficacy of @entity99 ( @entity99 ) for @entity1 with advanced HCCs. METHODS: Forty-eight @entity157 @entity1 with @entity715 were treated by @entity99 via a subcutaneously implanted injection port. Of these, 14 had @entity715 in the second portal branch and 34 @entity1 had @entity715 in the first portal branch or in the main portal trunk. One course of chemotherapy consisted of daily @entity900 (7 mg/m(2) for 1 hour on Days 1-5) followed by @entity1487 (170 mg/m(2) for 5 hours on Days 1-5). @entity1 were scheduled to receive four serial courses of @entity99 . Responders were defined as having either a complete response (CR) or partial response (PR) and nonresponders were defined as exhibiting stable disease or @entity74 . The prognosis after @entity99 and factors related to survival were analyzed. RESULTS: Following @entity99 , 4 and 19 @entity1 exhibited a CR and PR, respectively (response rate = 48%). The 1, 2, 3, and 5-year cumulative survival rates of 48 @entity1 treated with @entity99 were 45%, 31%, 25%, and 11%, respectively. Median survival periods for 23 responders and 25 nonresponders were 31.6 (range, 8.3-76.9) months and 5.4 (1.9-29.0) months, respectively. Therapeutic effect (P < 0.001) and hepatic reserve capacity (P = 0.021) were identified as significant prognostic factors by univariate analysis. Multivariate analysis identified only therapeutic effect as being significantly related to survival. CONCLUSIONS: @entity99 using low-dose @entity900 and @entity1487 may be a useful therapeutic option for @entity1 with advanced @entity157 with @entity715 . @entity157 @entity1 with @entity715 who respond to @entity99 could certainly have survival benefits.
